Drug-Induced Hypophosphatemia: Current Insights

Area of Science:

• Biochemistry and Pharmacology
• Clinical Medicine
• Drug Metabolism and Interactions

Background:

• Phosphate is crucial for energy metabolism, nucleic acid synthesis, cellular signaling, and bone formation.
• Hypophosphatemia (serum phosphate < 2.5 mg/dL) is a frequent complication of numerous medications.
• Commonly implicated drugs include diuretics, bisphosphonates, antibiotics, insulin, antacids, teriparatide, denosumab, parenteral iron, antivirals, and antineoplastics.

Purpose of the Study:

• To review drug-associated hypophosphatemia, detailing its underlying mechanisms.
• To provide clinicians with updated knowledge for early diagnosis and effective management.
• To enhance understanding of this adverse drug effect across various therapeutic classes.

Main Methods:

• Comprehensive literature review of drug-induced hypophosphatemia.
• Analysis of biochemical pathways affected by low phosphate levels.
• Synthesis of current clinical data on diagnosis and management strategies.

Main Results:

• Identified a broad spectrum of drugs, both common and novel, that can lead to hypophosphatemia.
• Elucidated the diverse mechanisms through which these drugs interfere with phosphate homeostasis.
• Highlighted the clinical significance of recognizing and managing drug-associated hypophosphatemia.

Conclusions:

• Drug-associated hypophosphatemia is an important clinical issue requiring heightened awareness.
• Understanding the mechanisms is key to anticipating and managing this electrolyte disturbance.
• Prompt diagnosis and appropriate management are essential for patient safety and therapeutic success.